Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Biopharma Adopts Generative AI, The ‘People Element’ Is Crucial To Success

Executive Summary

After a year of hype around generative AI, the question is can it deliver productivity wins for biopharma? Consultants at BCG give insights into successes and failures of early projects and emphasize that putting people first is key to success.

You may also be interested in...



Abingworth Adds Stakes To Gilead’s Trodelvy Gamble

The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.

As Vyvgart Surges To Blockbuster Status, Argenx Maps Out Expansion Plans

The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.

Idorsia Asset Sell Off Continues But Future Still Up In The Air

A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel